Mirvaso Gel (Brimonidine 0.33%)

Mirvaso is the new FDA approved treatment from Galderma that was previously known as Sansrosa, CD07805/47 and Col-118. Mirvaso is the only topical treatment officially approved for the relief of the red face of rosacea. Mirvaso is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours.

See below for Mirvaso User Reviews, news and updates

Recent Rosacea Blog Posts

Mirvaso plus Soolantra – better together

This just published research suggests that you can successfully treat rosacea with Mirvaso and Soolantra at the same time. So if you are suffering from the red face and pustules and papules of rosacea, this paper suggests that using Mirvaso and Soolantra together is a viable option. Previously Mirvaso and Soolantra have been shown to […]

Continue Reading

Galderma CareConnect Savings Card

A little known program from Galderma may offer access to expensive rosacea treatments for many currently unaware rosacea sufferers. Galderma CareConnect offers rebates, for insured and fully uninsured rosacea sufferers for prescription treatments well known to rosacea sufferers; – Oracea, Mirvaso, Soolantra and Metrogel. The program is being promoted as being offered by `any US […]

Continue Reading

Mirvaso rebound after 2 years of happiness

A paper in the Journal of Drugs in Dermatology is detailing a case report where rebound associated with Mirvaso occured after 2 years of otherwise successful use. The patient was enjoying the benefits of Mirvaso – a blanching of their erythema, for 2 years when they unexpectedly experienced rebound redness. The patient noted that Mirvaso […]

Continue Reading

Allergan – Rhofade has no rebound

In a document prepared for Allergan’s November 4, 2015 R&D Day presentation, Allergan is highlighting the development of its soon to be approved oxymetazoline 1% cream for rosacea. The slides relating to Oxymetazoline show the features of this product, along with other products in development, that Allergan wants to promote to investors. In the presentation […]

Continue Reading

Waiting for Azultro, Afrin users beware

Rosacea sufferers learnt recently that Allergan’s Oxymetazoline based topical (likely to be called Azultro) has been submitted for FDA approval and could be approved in the first half of 2017. For those wanting to try this claimed gentler-than-Mirvaso treatment for a red face, waiting for another year can seem like an eternity. If you are […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.